准STK17B激酶激活铁亡并抑制多发性骨髓瘤中药物耐药性
Zhibo Yan1, Zhannan Han1, Yihui Wang1
1Duke University, Durham, North Carolina, United States.
Blood
|September 15, 2025
概括
我们发现STK17B激酶抑制了多发性骨髓瘤 (MM) 中细胞死亡途径铁亡. 抑制STK17B显示出通过重新敏感化癌细胞和减少瘤生长来治疗MM的前景.
科学领域:
- 在瘤学瘤学.
- 细胞死亡机制 细胞死亡机制
- 分子生物学分子生物学
背景情况:
- 多发性骨髓瘤 (MM) 是一种无法治愈的血细胞癌.
- MM的进展与抑制的铁亡有关,一种依赖于铁的细胞死亡.
- 在MM中抑制铁亡的机制尚不清楚.
研究的目的:
- 确定MM中抑制铁亡的关键调节剂.
- 研究STK17B激酶作为潜在的治疗点.
- 阐明STK17B影响铁亡的分子机制.
主要方法:
- 在MM患者样本中评估STK17B水平.
- 在MM细胞系和小鼠模型中抑制STK17B.
- 使用近距离标签和蛋白质组分析.
- 研究了STK17B对铁代谢和STAT3信号传递的影响.
主要成果:
- 升高的STK17B与MM患者的生存率和复发率差相关.
- 抑制STK17B会恢复铁,提高对治疗的敏感性,并减少瘤的生长.
- STK17B直接针对IREB2和HSPB1,调节铁的稳态.
- STK17B间接维持STAT3酸化,这是一个关键的MM驱动器.
结论:
- STK17B是多发性骨髓瘤中铁亡的关键抑制剂.
- STK17B-IREB2/HSPB1信号轴是一个新的治疗点.
- 针对STK17B提供了一种潜在的策略,以克服MM的耐药性.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K


